Title of article :
The effects of nanomicelle of curcumin on the matrix metalloproteinase (MMP-2, 9) activity and expression in patients with coronary artery disease (CAD): A randomized controlled clinical trial
Author/Authors :
Mogharrabi, Marzieh Mashhad University of Medical Sciences - School of Medicine - Department of Clinical Biochemistry , Rahimi, Hamid Reza Mashhad University of Medical Sciences - Neurogenic Inflammation Research Center , Hasanzadeh, Shima Mashhad University of Medical Sciences - School of Medicine - Department of Clinical Biochemistry , Dastani, Mostafa Mashhad University of Medical Sciences - School of Medicine - Cardiovascular Research Center , Kazemi-Oskuee, Reza Mashhad University of Medical Sciences - School of Medicine - Department of Medical Biotechnology , Akhlaghi, Saeed Mashhad University of Medical Sciences - School of Medicine - Department of Psychiatry , Soukhtanloo, Mohammad Mashhad University of Medical Sciences - School of Medicine - Department of Clinical Biochemistry
Abstract :
BACKGROUND: Coronary artery disease (CAD) is the most common type of cardiovascular
disease. Increasing the expression and activity of matrix metalloproteinases (MMPs) facilitates
vascular remodeling and cardiovascular complications. Curcumin (the active ingredient of
turmeric) is a potent natural anti-inflammatory agent, with cardiovascular protective effects.
The present study was a clinical trial for investigating the effects of curcumin on activity and
gene expression of MMP-2 and MMP-9 in patients with CAD.
METHODS: In this study, 70 patients with CAD (with 40%-50% stenosis) were randomly divided
into two groups of curcumin (80 mg nanomicelle per day) and placebo. The intervention lasted
3 months. The activity levels of MMP-2 and MMP-9 in serum samples of patients were
measured using gelatin zymography assay before and after the intervention. MMP-2 and MMP-
9 gene expression in peripheral blood mononuclear cells (PBMCs) was also analyzed using realtime
polymerase chain reaction (PCR). Statistical significance was set at P < 0.0500.
RESULTS: After 3 months of medication, the expression of MMP-9 produced by PBMCs significantly
decreased in the curcumin group (0.811 ± 0.25) in comparison with the placebo group
(2.23 ± 0.94) (P < 0.0001). Furthermore, the zymographic analysis showed that the administration
of curcumin significantly inhibited the activity levels of MMP-2 (12469.7 ± 5308.64 pixels) and
MMP-9 (14007.2 ± 5371.67 pixels) in comparison with that in patients receiving placebo (MMP-2:
17613.8 ± 5250.68 pixels; MMP-9: 20010.1 ± 3259.37 pixels) (P < 0.0500).
CONCLUSION: Our results show that curcumin can significantly reduce the expression and
activity of MMP-2 and MMP-9. Because of the anti-inflammatory effects of curcumin, this
compound can be considered as a new strategy for the prevention of cardiovascular events.
Keywords :
Curcumin , Matrix Metalloproteinases , Coronary Artery Disease
Journal title :
Arya Atherosclerosis
